Boosted by deferred revenue, the pharmaceutical company’s vaccine sales skyrocket in Q1, while its 2023 sales outlook remains unchanged
04 May 2023 - 15:59
by Agency Staff
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Moderna on Thursday reported stronger-than-expected sales for its Covid-19 vaccine for the first quarter, driven by a surge of revenue deferred from 2022, but left its 2023 sales expectations unchanged.
The vaccine-maker posted a profit of 19c per share, compared with analysts’ expectations for a loss of $1.77 per share, in part because sales were higher than expected.
Shares of the company were up nearly 2% in choppy premarket trade.
Moderna said it continued to expect Covid-19 vaccine sales of $5bn for the year based on advance purchase agreements. It added it was having discussions about new contracts with customers in Europe, Japan and in the US.
The $1.83bn of sales for its Covid-19 vaccine, Spikevax, represents most of the $2bn expected in the first half of the year for advanced purchase agreements and double the average analyst estimate of $998m, according to Refinitiv IBES data.
Moderna expects an additional $3bn in deferred vaccine revenue in the second half of 2023.
“Today’s beat and 2023 reiteration of guidance along with ongoing negotiations in three regions should support some confidence on the 2023 base business of $5bn-$7bn,” said Jefferies analyst Michael Yee.
Moderna continues to expect the US annual Covid-19 market to be 100-million doses, she added.
The results came two days after rival Pfizer reported better-than-expected Covid-19 vaccine sales for the first quarter and maintained its expectations for full-year sales.
Moderna said on Thursday it now expects a tax benefit of $300m-$500m for the year due to credits for research & development and certain one-off items.
The company had generated about $36bn in sales over the last two years from its Covid-19 vaccine, its only commercial product and one of the most widely used shots for the virus.
Demand for the vaccine has since fallen globally, and the company in February effectively forecast a possible net loss for 2023, calling it a transition year before it starts sales of its potential new vaccines for respiratory syncytial virus (RSV) and flu.
All of its vaccines are based on the same mRNA platform as its Covid-19 product.
Moderna said on Thursday it was preparing for potential commercial launches of its RSV and flu vaccines in 2024. Longer term, the company has also teamed up with Merck on a cancer vaccine that works in concert with Merck’s immunotherapy Keytruda.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Moderna’s Q1 Covid-19 vaccine sales soar, surpassing expectations
Boosted by deferred revenue, the pharmaceutical company’s vaccine sales skyrocket in Q1, while its 2023 sales outlook remains unchanged
Moderna on Thursday reported stronger-than-expected sales for its Covid-19 vaccine for the first quarter, driven by a surge of revenue deferred from 2022, but left its 2023 sales expectations unchanged.
The vaccine-maker posted a profit of 19c per share, compared with analysts’ expectations for a loss of $1.77 per share, in part because sales were higher than expected.
Shares of the company were up nearly 2% in choppy premarket trade.
Moderna said it continued to expect Covid-19 vaccine sales of $5bn for the year based on advance purchase agreements. It added it was having discussions about new contracts with customers in Europe, Japan and in the US.
The $1.83bn of sales for its Covid-19 vaccine, Spikevax, represents most of the $2bn expected in the first half of the year for advanced purchase agreements and double the average analyst estimate of $998m, according to Refinitiv IBES data.
Moderna expects an additional $3bn in deferred vaccine revenue in the second half of 2023.
“Today’s beat and 2023 reiteration of guidance along with ongoing negotiations in three regions should support some confidence on the 2023 base business of $5bn-$7bn,” said Jefferies analyst Michael Yee.
Moderna continues to expect the US annual Covid-19 market to be 100-million doses, she added.
The results came two days after rival Pfizer reported better-than-expected Covid-19 vaccine sales for the first quarter and maintained its expectations for full-year sales.
Moderna said on Thursday it now expects a tax benefit of $300m-$500m for the year due to credits for research & development and certain one-off items.
The company had generated about $36bn in sales over the last two years from its Covid-19 vaccine, its only commercial product and one of the most widely used shots for the virus.
Demand for the vaccine has since fallen globally, and the company in February effectively forecast a possible net loss for 2023, calling it a transition year before it starts sales of its potential new vaccines for respiratory syncytial virus (RSV) and flu.
All of its vaccines are based on the same mRNA platform as its Covid-19 product.
Moderna said on Thursday it was preparing for potential commercial launches of its RSV and flu vaccines in 2024. Longer term, the company has also teamed up with Merck on a cancer vaccine that works in concert with Merck’s immunotherapy Keytruda.
Reuters
Pharma took in $100bn from Covid-19 — what will they do with it, investors ask
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
WHO launches mRNA vaccine hub in Cape Town
Pharma took in $100bn from Covid-19 — what will they do with it, investors ask
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.